Jonathan S. Berek

Back to Profile

Publication Details

  • Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy.

    Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L. Clin Cancer Res. 2004; 10 (8): 2681-6

    We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma.

    PubMedID: 15102671

Stanford Medicine Resources:

Footer Links: